首页>
外国专利>
Immunotherapy of B-cell malignancies using anti-CD22 and anti-CD20 antibodies in combination
Immunotherapy of B-cell malignancies using anti-CD22 and anti-CD20 antibodies in combination
展开▼
机译:联合使用抗CD22和抗CD20抗体对B细胞恶性肿瘤进行免疫治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.
展开▼